Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: a randomized, multicenter, phase II study. Canadian Cancer Trials Group (CCTG) IND.219

Barbara Melosky,Penelope Bradbury,Dongsheng Tu,Marie Florescu,Anthony Reiman,Garth Nicholas,Naveen Basappa,Jeffrey Rothenstein,John R. Goffin,Scott A. Laurie,Paul Wheatley-Price,Natasha Leighl,Glenwood Goss,M. Neil Reaume,Charles Butts,Nevin Murray,Cynthia Card,Jenny Ko,Normand Blais,Samantha Gray,Hongbo Lui, Pamela Brown-Walker, Pardeep Kaurah, Leah M. Prentice,Lesley Seymour

Lung Cancer（2019）

引用 24|浏览96

暂无评分

摘要

•No difference in efficacy/toxicity for intermittent or continuous selumetinib.•Combination of selumetinib and platinum associated with higher ORR in first line.•No association between KRAS status and efficacy.•Skin and GI adverse events were more common with addition of selumetinib.•High incidence of venous thromboembolism was seen in all arms.

查看译文

关键词

NSCLC,MEK,KRAS,Selumetinib,Chemotherapy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要